Japan Gastrointestinal Therapeutics Market, 2025-2033
The gastrointestinal therapeutics market in Japan is expected to reach a projected revenue of US$ 2,909.3 million by 2033. A compound annual growth rate of 1.7% is expected of Japan gastrointestinal therapeutics market from 2026 to 2033.
Japan gastrointestinal therapeutics market highlights
The Japan gastrointestinal therapeutics market generated a revenue of USD 2,547.3 million in 2025 and is expected to reach USD 2,909.3 million by 2033.
The Japan market is expected to grow at a CAGR of 1.7% from 2026 to 2033.
In terms of segment, branded was the largest revenue generating drug type in 2025.
Generics is the most lucrative drug type segment registering the fastest growth during the forecast period.
Gastrointestinal therapeutics market data book summary
Market revenue in 2025
USD 2,547.3 million
Market revenue in 2033
USD 2,909.3 million
Growth rate
1.7% (CAGR from 2026 to 2033)
Largest segment
Branded
Fastest growing segment
Generics
Historical data
2021 - 2024
Base year
2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million
Market segmentation
Branded, Generics
Key market players worldwide
AbbVie Inc, AstraZeneca PLC, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Bayer AG, Abbott Laboratories, Janssen Pharmaceuticals, Sun Pharmaceutical Industries, Cipla Ltd DR, Gilead Sciences Inc, Biogen Inc, Organon & Co Ordinary Shares
Other key industry trends
In terms of revenue, Japan accounted for 6.0% of the global gastrointestinal therapeutics market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Asia Pacific, China gastrointestinal therapeutics market is projected to lead the regional market in terms of revenue in 2033.
China is the fastest growing regional market in Asia Pacific and is projected to reach USD 4,394.9 million by 2033.
Japan held the largest market share in 2019, owing to the rise in product launches as well as approvals, growing number of R&D activities, high number of initiatives undertaken by market players & government organizations, and high prevalence of ulcerative colitis, Crohn’s disease, & GERD.
Growing number of drug approvals is another factor aiding growth in the country. For instance, in May 2019, Takeda Pharmaceutical Company Limited announced that the Ministry of Health, Labour and Welfare approved its drug Entyvio for treatment of Crohn’s disease.
The drug was also approved in 2018 for treatment of active ulcerative colitis. Thus, rise in the number of drug approvals for gastrointestinal diseases can be attributed to the largest share as well as future growth.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Gastrointestinal Therapeutics Market will help companies and investors design strategic landscapes.
Branded was the largest segment with a revenue share of 67.75% in 2025.
Horizon Databook has segmented the Japan gastrointestinal therapeutics market based on branded, generics covering the revenue growth of each sub-segment from 2021 to 2033.
Japan held the largest market share in 2019, owing to the rise in product launches as well as approvals, growing number of R&D activities, high number of initiatives undertaken by market players & government organizations, and high prevalence of ulcerative colitis, Crohn’s disease, & GERD.
Growing number of drug approvals is another factor aiding growth in the country. For instance, in May 2019, Takeda Pharmaceutical Company Limited announced that the Ministry of Health, Labour and Welfare approved its drug Entyvio for treatment of Crohn’s disease.
The drug was also approved in 2018 for treatment of active ulcerative colitis. Thus, rise in the number of drug approvals for gastrointestinal diseases can be attributed to the largest share as well as future growth.
Japan Gastrointestinal Therapeutics Market Drug Type Outlook (Revenue, USD Million , 2021-2033)
Branded
Generics
Japan Gastrointestinal Therapeutics Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
Aminosalicylates
Digestive Enzymes
Proton Pump Inhibitors
Laxatives
Anti-emetics
H2 Antagonists
Anti-diarrheals
Biologics/Biosimilar
Other Drug Classes
Japan Gastrointestinal Therapeutics Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
Oral
Injectables
Others Route of Administrations
Japan Gastrointestinal Therapeutics Market Application Outlook (Revenue, USD Million , 2021-2033)
Crohn's disease
Ulcerative colitis
GERD
IBS
Others Applications
Japan Gastrointestinal Therapeutics Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Reasons to subscribe to gastrointestinal therapeutics market databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of gastrointestinal therapeutics market databook
Our clientele includes a mix of gastrointestinal therapeutics market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan gastrointestinal therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Japan gastrointestinal therapeutics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Japan Gastrointestinal Therapeutics Market, 2021-2033 (US$M)